c-Myc-PD-L1 Axis Sustained Gemcitabine-Resistance in Pancreatic Cancer

• Main Authors: Jingjing Yao (Author), Min Huang (Author), Qinghong Shen (Author), Ming Ding (Author), Shaofang Yu (Author), Yajuan Guo (Author), Yuefang Lin (Author), Yaqiu Zheng (Author), Wenbo Chen (Author), Wenxin Yan (Author), Zhongqiu Liu (Author), Dawei Wang (Author), Ming Hu (Author), Linlin Lu (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Pancreatic cancer ranks fourth among cancer-related deaths, with a 5-years overall survival rate being below 10%. Gemcitabine (dFdC) has been considered the first-line drug for patients with pancreatic cancer. However, the clinical effectiveness is less than 20% due to drug resistance. Most importan...